20 participants
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2021-11-04
Conditions
- HIV Infections
- HIV Seronegativity
Interventions
- BIOLOGICAL
No Results Yet